ANDA 206799, held by Novel Laboratories. Voriconazole.
As of Nov 21, 2026, ANDA 206799 (Voriconazole), held by Novel Laboratories, was first approved by FDA on May 31, 2016, with 7 approved supplements and 0 published complete response letters.
Voriconazole is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis Candidemia in non-neutropenics and other deep tissue Candida infections Esophageal candidiasis Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy 1.1 Invasive Aspergillosis Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Voriconazole200MG/5ML · for suspension;oral | Voriconazole | Rx |
| Sep 30, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 20, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 14, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 14, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 14, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 14, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 14, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 31, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters